Kornimate/medical-research-clean huggingface dataset:
human chorionic gonadotropin (hcg) test: a novel method to evaluate the ovarian reserve

Conditions: Infertility

Summary: in an era of delayed fertility plans, there is an increasing need for a reliable method to predict ovarian reserve and responsiveness. the current tests include serum fsh, inhibin b, mullerian inhibiting factor (mif) and ultrasonographic measures such as ovarian volume and number of antral follicles are non-specific and with questionable reliability. the biochemical tests represent the function of production of androgens, as a predictor of ovarian reserve, has not been tested yet. working hypothesis and aims: testing the prognostic capability of hcg stimulating test of theca cells for estimating the ovarian reserve, and by that to calculate better the chance for ivf cycle success

20 women \>40 years old and 20 women \<35 years old, attended to our ivf unit were included in the study. another 20 other young women (\<35 years) with poor response in previous ivf cycles will be participate. all participants received a single hcg 10000 iu injection on cycle day 2-4. hormone levels of lh, fsh, e2, p, testosterone, androstendione and 17-ohp were taken prior to the injection and on days 1, 3 and 7 afterwards. hcg induced hormone levels will be compared with ivf results

Eligibility criteria:
inclusion criteria: * all women on ivf cycle exclusion criteria: * any allergy to injection of human chorionic gonadotropin before

Keywords: ivf ovarian reserve androgens thecal cells fertility agents, female
virtual reality in icu - partner

Conditions: Acute Respiratory Failure; Sepsis

Summary: this project is designed to have patients participate in a virtual environment with various tasks such as breathing exercises, games to help the brain, and techniques that promote relaxation while hospitalized in the intensive care unit (icu). the participation in research will last about 5 days and take about 15 to 45 minutes each day.

this is a research study about interacting and engaging in strategies to promote relaxation, improve mood, and stimulate thinking in patients in the intensive care unit (icu) in the hospital; called partner. partner is played by using a readily available virtual reality headset while patients are in the icu. the researchers hope to learn if engaging with exercises for emotional health and cognitive function reduces delirium and loneliness in the hospital. if patients agree, the patients will be asked to play parnter, with a virtual reality (vr) device to connect them to a virtual environment with games and/or relaxing scenes while in the icu. the virtual environment may include things such as breathing exercise, mindfulness training, and relaxation techniques.

Eligibility criteria:
inclusion criteria: * admitted to icu at university of kentucky for acute respiratory failure, sepsis or other exclusion criteria: * are less than 18 years of age * have a pre-existing neurologic disorder * have a pre-existing emotional or personality disorder * have a history or active mental health disorder or disease * experienced an acute neurologic event (e.g., stroke) * are currently pregnant * are a prisoner * receiving hospice care * have existing open wounds or pressure ulcers on head or neck

Keywords: virtual reality intensive care unit sepsis acute respiratory failure
a phase ib/ii clinical study of shr-a2009 for injection in combination with other antitumor therapies in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this study is an open-label, multicenter phase ib/ii clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of shr-a2009 for injection in combination with other antitumor therapies in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. age 18 to 75 years old (inclusive), female or male 2. subjects with unresectable locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology 3. previously treated by egfr-tki or other standard treatment or have not been treated for metastatic setting; 4. at least one measurable tumor lesion according to recist v1.1 (enrollment of subjects with only non-target lesions is permitted in stage ib phase) 5. ecog performance score of 0-1; 6. expected survival time ≥ 12 weeks; 7. adequate bone marrow and organ function 8. subjects are required to give informed consent for this study prior to the trial and voluntarily sign a written informed consent form. exclusion criteria: 1. subjects with active central nervous system (cns) metastases. 2. spinal cord compression not cured by surgery and/or radiotherapy cannot be enrolled. 3. subjects with uncontrolled tumor-related pain 4. clinically uncontrollable third space fluid 5. received antitumor therapy such as chemotherapy within 4 weeks prior to the first dose of study drug; 6. received \>30 gy of non-thoracic radical radiation therapy within 4 weeks prior to the first administration of study drug; 7. major organ surgery or significant trauma within 4 weeks prior to first use of study drug; 8. concomitant other malignancies ≤ 5 years prior to first dose of study drug; 9. subjects with a history of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis; or other moderate-to-severe lung disease that severely affects lung function 10. serious cardiovascular disease 11. presence of refractory nausea, vomiting, chronic gastrointestinal disease, etc.; subjects with active, known or suspected autoimmune diseases 12. presence of severe infection within 4 weeks prior to first dose of study drug 13. subjects with clinically significant bleeding symptoms within 3 months prior to the first dose of study drug 14. arterial/venous thrombotic events within 3 months prior to the first study dose 15. history of immunodeficiency, including a positive hiv test 16. presence of active hepatitis b or c; 17. history of severe allergic reactions to other monoclonal antibodies or allergic reactions to any component of the shr-a2009 product. 18. known history of alcohol or drug dependence or addiction; 19. persons with mental disorders or poor compliance;
procalcitonin levels as a predictor of bacteremia in febrile pediatric oncology patients-pilot study

Conditions: Cancer; Bacteremia

Summary: fevers raise the concern for serious bacterial infections in pediatric oncology patients receiving chemotherapy. the gold standard for diagnosing bacteremia (bacterial infection of the blood) is a blood culture. however, bacterial growth may not occur for 48 hours or there can be a false negative result. thus, the biomarker, procalcitonin, has been investigated for its predictive ability to identify bacteremia earlier than blood culture. we believe that procalcitonin can assist in differentiating bacteremia from non-bacteremia infections in febrile pediatric oncology patients. a reliable predictor of bacteremia infections in pediatric oncology patients should decrease hospitalizations for fever and unnecessary antibiotic treatment. in our study we will measure procalcitonin levels in pediatric oncology patients presenting with fever. we will measure procalcitonin at the time of admission which is part of our standard of care for febrile pediatric oncology admissions. for the purpose of our study, we will additionally measure procalcitonin levels at 12 hours and at 24 hours post admission. we will examine procalcitonin levels at these three timepoints to determine if elevated procalcitonin levels predict bacteremia in pediatric oncology patients with and without neutropenia.


Eligibility criteria:
inclusion criteria: * children between the ages of birth to seventeen years. * present to charleston area medical center women and children's hospital * existing pediatric oncology diagnosis. * temperature greater than 38.0 c or 100.5 fahrenheit. * central venous access or functional port available. exclusion criteria: * any non-pediatric (eighteen years and above) oncology patient or a non-oncology patient. * the patient does not have central venous access or a port from which the blood can be drawn.
does bariatric surgery changes eating habits and addiction in morbid obesity?

Conditions: Obesity

Summary: 1. obesity is a big health problem worldwide. 2. mostly obese people have food addiction and bad eating habits. 3. bariatric surgery is a good alternative for patients who failed to loose weight with other measures like behavioral changes, activities and sports, diet, etc.. 4. the investigators know the changes occurred after surgery in eating habits due to restrictive and malabsorptive feature of the surgery performed. 5. there is no study in the literature to measure these changes. 6. the investigators will try to detect these kind of behavioral changes by a survey before and after surgery.


Eligibility criteria:
inclusion criteria: * patients with bmi \> 40 kg/m2 * patients with bmi \> 35 kg7m2 \< 40 kg/m2 but with comorbidity * patients \> 18 years old * patients who sign the inform consent * patients who have no psychiatric disease * patients who have no endocrine disorders exclusion criteria: * all obese patients who do not fulfill the criteria above mentioned

Keywords: obesity bariatric surgery behavioral changes eating habits eating addiction
an educational intervention to improve resident comfort with communication at the end of life

Conditions: End of Life Communication

Summary: the purpose of this study is to investigate whether the addition of teaching on communication at the end of life to the pre-existing resident curriculum will positively impact residents' knowledge and attitudes regarding communication at the end of life.

previous research has demonstrated a lack of resident training in communication at the end of life. this can lead to anxiety on the part of residents and poor experiences with these conversations. residents at ucsf, and affiliated sites, participate in a daily formal teaching session from 12-1 pm and an informal case conference, known as morning report, from 7:30-8:30 am (8-9 am at vamc). we propose to administer a pre-intervention survey to residents to assess knowledge and attitudes regarding communication at the end of life. over two months, residents will receive one lecture during the noon session. clinical cases will be presented for discussion during three sessions of morning report. all sessions are voluntary and take place at all three training sites, ucsf, sfgh, and the vamc. as residents rotate every two months between the inpatient and outpatient settings, the intervention will be repeated once to ensure that the majority of residents have the opportunity to participate. a post-intervention survey, identical to the pre-intervention survey, will be administered to assess for impact of the educational intervention. this project only involves ucsf internal medicine residents. no patients will be involved in this study.

Eligibility criteria:
inclusion criteria: * ucsf internal medicine resident exclusion criteria: * not ucsf internal medicine resident
ostomy primary closure with 0.1% betaine/polyhexanide wound irrigation compared to pursestring closure

Conditions: Surgical Site Infection; Wound Surgical; Colorectal Disorders

Summary: the goal of this clinical trial is to compare two types of closure in patients with ostomies that are ready for closure. the main questions it aims to answer are: 1. surgical site infection rates 2. patient quality of life 3. time to wound healing participants will undergo either complete ostomy wound closure after washing out the wound with prontosan, or their ostomy wound will be closed using the pursestring method, where the wound will be left partially open and allowed to heal from the inside out. researchers will compare these two groups' outcomes (questions to be answered) as listed above.

surgical site infection (ssi) is a common yet potentially serious and devastating complication in colorectal surgery, with rates of up to 25%, many of which are preventable. in stoma closure, ssi rates have been reported as up to 40% with conventional closure techniques. ssi adds more burden to the patient, requiring additional therapy, such as antibiotics, wound drainage, and even wound debridement. this results in longer hospital length of stay and can ultimately negatively impact a patient's quality of life. additionally, allowing a wound to heal by secondary intention has been demonstrated to have worse cosmetic outcomes compared to primary closure, which may also impact quality of life (qol) for patients. the investigators aim to investigate the outcomes (including ssi rates and qol) of patients who underwent two different standards of care in ostomy closure: primary skin closure after usage of prontosan, a 0.1% betaine and 0.1 % polyhexamethylene biguanide antimicrobial solution, and secondary intention healing after pursestring closure. comparing these two closure methods, may yield further insight into better treatment options for wound closures in colorectal surgery patients. patients will be recruited in the unlv colorectal clinic at their appointments, and surgeries will be done at university medical center. patient recruitment and informed consent will be performed by the co-investigators. the sample size is calculated for a non-inferiority trial with a 2.5% level of significance, 90% power of test and an expected ssi rate of 3% for the purse-string closure group and 25.9% for the primary wound closure without 0.1% betaine/0.1% polyhexanide). the sample size needed is 42 patients in each study arm with an assumed 20% attrition rate. data will be analyzed by the statistician.

Eligibility criteria:
inclusion criteria: * all patients 18 years or older with an diverting loop ileostomy reversal indication will be enrolled * signed consent exclusion criteria: * under 18 years old, unable to provide consent, has a parastomal hernia requiring mesh repair, or has an end ileostomy

Keywords: ostomy surgical site infection primary closure secondary closure
randomized clinical trial of triptolide woldifii for autosomal dominant polycystic kidney disease

Conditions: Polycystic Kidney

Summary: triptolide has been approve effective in animal model.

randomized

Eligibility criteria:
inclusion criteria: * clinically established adpkd * egfr\>30ml/min. * chinese nationality exclusion criteria: * uncontrolled infections * non-adpkd complications

Keywords: polycystic kidney disease tripterygium wilfordii
continuous infusion of palonosetron for preventing of postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: the purpose of this study is to determine whether continuous infusion of palonosetron after its prophylactic single injection can further reduce the incidence of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * asa physical status 1 or 2 * elective gynaecological laparoscopic surgery of ≥ 1h duration exclusion criteria: * anti-emetics, steroids, or psychoactive medications within 24 h of study initiation * vomiting or retching in the 24 h preceding surgery * cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry * ongoing vomiting from gastrointestinal disease
study of spg302 in adult participants with mild-to-moderate alzheimer's disease (ad)

Conditions: Alzheimer Disease

Summary: this phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of spg302 in adult participants with mild-to-moderate ad.

this is a phase 2, multicenter study to assess the safety, tolerability, cns effects, pharmacokinetics, pharmacodynamics and clinical efficacy of spg302 in adult participants with mild-to-moderate ad. the study will consist of 2 parts: part a: placebo-controlled, randomized, safety and preliminary efficacy cohort with daily dosing for 28 day cycles part b: a randomized expansion cohort of daily dosing for 28 day cycles

Eligibility criteria:
inclusion criteria: * age 45-85 * diagnosis of mild to moderate ad * clinical laboratory values within normal range or \< 1.5 times uln * if receiving ad-specific treatment, have been on stable dose for ≥ 3 months prior to first dose of study drug. * life expectancy of \>2 years * able and willing to provide written informed consent exclusion criteria: * any physical or psychological condition that prohibits study completion * known cardiac disease * active or history of malignancy in the past 5 years * serious infection that will not be resolved by first day of study intervention. * history of clinically significant cns event or diagnosis in the past 5 years. * acute illness within 30 days of day 1 * history of suicidal behavior or suicidal ideation * history of chronic alcohol use or substance abuse in the last 5 years * hiv, hepatitis b and/or hepatitis c positive * vaccines within 14 days * receipt of investigational products within 30 days * blood donation within 30 days * pregnant or breastfeeding

Keywords: alzheimer disease synapse neural connectivity dementia
children's deep neck infections at the montpellier hospital

Conditions: Deep Neck Infections

Summary: to descride the clinical presentation, diagnosis, management and complications of children with a deep neck infection. a retrospective chart review was conducted at the montpellier hospital in france. all children aged less than 18 years who had been admitted with a diagnosis of cervical phlegmon, tonsillar abscesses, retropharyngeal or parapharyngeal abscesses between january 2015 and december 2017 were included. the investigators collected the demographic, biological, radiological data and treatment received of the patients to the admision. the results of the bacteriological samples were collected. the investigators compared our results to those of the 10-year cohort. the investigators wish to compare the duration of hospitalization and the duration of the fever enter the group treated by alone antibiotic and the group treated by antibiotic and surgical drainage


Eligibility criteria:
inclusion criteria: * under 18 years old * hospitalized for acute pharyngeal infection ( cervical phlegmon, tonsillar abscesses, retropharyngeal or parapharyngeal abscesses) exclusion criteria: * neck infection in the context of immune deficiency * malignancy or post-traumatic disease * others deep neck infections: angina, otitis, sinusitis, ethmoiditis, mastoiditis.

Keywords: cervical phlegmon tonsillar abscesses retropharyngeal or parapharyngeal abscesses medical and chirurgical treatment bacteria in deep neck infections
study of transverse abdominis plane (tap) block in children undergoing hydrocelectomy and/or hernia repair surgery

Conditions: Hydrocele; Inguinal Hernia

Summary: study measures the difference in pain after hernia \&/or hydrocele repair based on site of local anesthesia injection.

this single-center, prospective, single blind, randomized study will enroll up to 50 subjects who are scheduled for elective hydrocelectomy and/or hernia repair. at beaumont health system, post-operative pain management in children is managed either via oral/parenteral opiates and opiate adjuncts, surgeon-administered field blocks (instillation of local anesthetics in the general area of incision), or via regional techniques (spinal, epidural, or peripheral nerve blocks). we have designed this study to determine if there is improved qualitative and quantitative post-operative pain control in patients receiving tap block versus intraoperative peri-incisional, surgeon administered field block. once informed consent has been given, each patient will be randomized (like flip of the coin) to either transverse abdominis plane block (tap block)or surgeon administered anesthesia.

Eligibility criteria:
inclusion criteria: * children 2-8 years of age * elective inguinal hernia repair, inguinal hernia repair with peritoneoscopy and/or hydrocelectomy to be performed in the center for children's surgery, beaumont hospital, royal oak * american society of anesthesiologists physical status classification 1 and 2 (patients that have either no systemic illness, or mild systemic disease that is well controlled, eg. mild asthma) exclusion criteria: * history of allergy to study medications * enrollment in concurrent research study * pregnant patients\* * students/trainees/staff\* * mentally disabled/cognitively impaired\*
study on the device "gondola" for motor rehabilitation in parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this research study is to evaluate safety and effectiveness of the automated mechanical peripheral stimulation (amps) therapy given via the gondola™ device to improving gait and gait related disorders in patients with parkinson'disease (pd). gondola® is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. the device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (automated mechanical peripheral stimulation - amps); the therapy requires less than 2 minutes.

the proposed project, through a randomized multicentric, placebo controlled double-blind crossover trial aimed at evaluating the effectiveness of amps gondola therapy versus sham gondola therapy in pd subjects. 132 in/outpatients with pd will be recruited. subjects will be randomized in 2 groups, one starting with amps treatment, the other with placebo treatment. at the end of the first cycle of 6 stimulations over a 3 weeks' time (amps or sham), all subjects will undergo a washout period of minimum 6 weeks, then will undergo another equivalent treatment cycle (sham or amps); a follow up valuation 14 days after the end of each treatment cycle will be performed. this project is aimed at studying and documenting the effects of the amps treatment given to pd patients via the gondola device in: 1. improving gait, reducing bradykinesia, treating freezing of gait symptom; 2. improving updrs ii and iii scores; 3. improving balance. another goal of the study is to document the safety of the gondola device.

Eligibility criteria:
inclusion criteria: * patients with clinically chronic and stable pd, confirmed according to the uk parkinson's disease society brain bank clinical diagnosis criteria (ukpdsbbc); * age 45 and older; * hoehn \& yahr (h\&y) stage equal or higher than 2 in on state; * ability to walk autonomously or with minimal assistance for a 10 meters' distance in off state; * antiparkinsonian treatment at a stable and optimized daily dosage during the 4 weeks prior to the study. exclusion criteria * any advanced, severe or unstable disease other than pd, which may interfere with the primary and secondary study outcome evaluations (autonomic dysfunction, diabetes, renal or hepatic failure, neoplasia, balance and gait problems of other origin). * cognitive impairment with moca \< 18 * any peripheral neurological or musculoskeletal conditions that may alter balance and/or gait. * severe lower limb injuries in the previous 6 months. * history of neurosurgery or orthopedic surgery. * history of epilepsy. * any drug treatment not intended to treat pd that may alter cognitive and/or motor performance. * history of depression or other psychiatric disorders. * severe obesity defined as a bmi greater than 35.

Keywords: automated mechanical peripheral stimulation (amps) gait disorders